The potentially devastating consequences of a relapse in patients with schizophrenia and the substantial risk of relapse associated with even partial compliance with therapy have made compliance a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rates of adverse events were similar in both dosing ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a long-acting subcutaneous risperidone injection for the treatment of schizophrenia in adults.

The RISE study 7 was a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of risperidone extended-release injectable suspension for subcutaneous use as a ...

The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular). The Food and Drug Administration (FDA) has approved Rykindo ® ...

Rykindo ® is a bi-weekly long-acting risperidone injection and is the first innovative therapy from Luye Pharma's Central Nervous System (CNS) product portfolio to be marketed in the United States.